Abstract. Gastric cancer is a common cancer of the gastrointestinal tract and the second most prevalent cause of cancer-associated mortality globally. Gastric cancer-associated mortality is increased in China compared with that in other countries. Key contributors to the poor prognosis of gastric cancer include late clinical presentation and genetic heterogeneity. Treatment based on the subtype of gastric cancer is important for effective therapy. The overexpression of the erb-b2 receptor tyrosine kinase 2 (ERBB2) gene and protein is associated with gastric cancer in humans. Chemotherapy and targeted therapy may control tumor growth and recurrence, which is an important function of conversion surgery. The present study reported a patient diagnosed with gastric cancer with multiple abdominal cavity and retroperitoneal lymph node metastases. ERBB2 amplification and overexpression were identified in both case reports presented. The patients were treated with four cycles of oxaliplatin, capecitabine and trastuzumab. Computed tomography revealed the lymph node metastases decreased in size following treatment, and surgical resection was performed. The four cycles of oxaliplatin, capecitabine and trastuzumab were continued subsequent to surgical resection at the administered dose. No recurrence was observed for >1 year after surgery. Trastuzumab combined with oxaliplatin and capecitabine as a conversion therapy regime for ERBB2-overexpressing advanced gastric adenocarcinoma increased the likelihood of successful surgical resection, and prolonged progression-free survival.

Introduction

In China, gastric cancer is the second most common type of cancer in males and the fourth most common type in females (1). The majority of patients with gastric cancer are diagnosed at the advanced stage, and the prognosis for patients with advanced gastric cancer is poor (2). Surgical resection is a cornerstone gastric cancer treatment, particularly during the early stage (3). Chemotherapy, radiotherapy, targeted therapy, palliative surgery and best supportive care have been used to treat patients with late stage gastric cancer (4). Conversion therapy may be feasible for prolonging overall survival. As gastric cancer is a heterogeneous disease, therapy should be performed based on subtype, and specific biomarkers and different treatment targets ought to be identified for each subtype (5). Erb-b2 receptor tyrosine kinase 2 (ERBB2) overexpression has been reported in 12-27 and 9-23% of patients with gastric cancer according to different studies (6-12). For patients with ERBB2+ gastric cancer, it has been advised that trastuzumab is administered as chemotherapy. The efficacy and safety of trastuzumab were evaluated in the Trastuzumab for Gastric Cancer (ToGA) trial (13), and it has been reported that trastuzumab may be used for conversion therapy (14,15). In the present study, the treatment regimen consisted of trastuzumab combined with oxaliplatin and capecitabine (XELOX), and was performed following surgery. Tumors were resected, conversion therapy was successful, and good clinical outcomes were achieved. Written informed consent was obtained from the patients for the present study and any accompanying images to be published. The Ethics Committee of Sichuan Cancer Hospital (Chengdu, China) approved the present study.

Case reports

Case 1. A 40-year-old female was admitted to Sichuan Cancer Hospital with a complaint of lower back pain for >1 month. An abdominal ultrasound revealed retroperitoneal lymph node enlargement. Gastroscopy revealed a poorly differentiated adenocarcinoma. Immunohistochemical analysis revealed ERBB2 overexpression (Fig. 2) (16). Computed tomography (CT) revealed that multiple lymph nodes were enlarged along the lesser curvature of the stomach, common hepatic artery, head of the pancreas, pancreatic vein, and the postcaval and para-aortic lymph nodes (Fig. 3). The clinical diagnosis was gastric body adenocarcinoma with abdominal cavity lymph node metastasis; the clinical stage was cT3N2M1. The patient received therapy that included a XELOX regimen and trastuzumab. The XELOX regimen comprised 130 mg/m²
oxaliplatin intravenous injection (iv) on day 1 and 1,250 mg/m² Xeloda® orally twice a day (p.o. b.i.d.) on days 1-14, repeated every 3 weeks. Trastuzumab was administered at 8 mg/kg iv on day 1 of the first cycle and then 6 mg/kg iv on day 1 of future cycles. Grade 1 neutropenia and grade 3 vomiting were observed based on the Common Terminology Criteria for Adverse Events (17). A CT scan was performed once the patient finished four cycles of the combination therapy. Partial response was observed using gastroscopy and CT (Figs. 4 and 5), and the clinical stage following four cycles of trastuzumab combined with chemotherapy was cT2N1M0 (18). Subsequently, the patient underwent total gastrectomy, D2 lymphadenectomy and Roux-en-Y anastomosis. Exploratory surgery revealed a 10x8 cm size tumor in the gastric body with multiple regional lymph nodes enlarged. However, no metastatic nodules were identified in the liver, parietal peritoneum, mesenterium, or pelvic floor. The macroscopic type of the tumor was classified as either the ulcerative or the infiltrative type according to Borrmann classification (19). Erosion mucosa, a small ulcer, and a rigid wall were detected. The pathological diagnosis was poorly differentiated adenocarcinoma of the gastric body. The tumor had invaded through the submucosa. Incisional margins were negative. In addition, cancer cells were identified in a lesser curvature lymph node (1/7 lymph nodes), whereas no cancer cells were observed in the other lymph nodes (0/16) (18). The pathological tumor-node-metastasis (TNM) stage was ypT1N1M0 (18). After six weeks following surgery, the patient received four cycles of XELOX and the trastuzumab regimen at the dose administered prior to surgery. After the therapy ceased, the patient received a follow-up every 3 months and remained disease-free at 12 months.

Case 2. A 67-year-old male was admitted to Sichuan Cancer Hospital with a complaint of abdominal pain for >3 weeks. Gastroscopy revealed an ulcer of the gastric cardia (Fig. 6) in July 2013. Biopsy identified a poorly differentiated carcinoma.
Immunohistochemical analysis revealed ERBB2 overexpression (Fig. 7) (16). CT demonstrated a thickening of the cardia wall and that multiple lymph nodes were enlarged in the region of the lesser curvature of the stomach (Fig. 8). The clinical diagnosis was cardia carcinoma with abdominal cavity lymph node metastasis. The clinical stage was cT4aN2M0. The patient received a neoadjuvant therapy that included a XELOX regimen and trastuzumab. The XELOX regimen comprised 130 mg/m² oxaliplatin iv on day 1 and 1,250 mg/m² Xeloda p.o. b.i.d. on days 1-14, repeated every 3 weeks. Trastuzumab was administered at a dose of 8 mg/kg iv on day 1 of the first cycle and then 6 mg/kg iv on day 1 of future cycles. Grade 2 neutropenia and grade 3 vomiting were observed. A CT scan was performed after the patient finished four cycles of the combination therapy. The lymph nodes along the lesser curvature and the tumor decreased in size following treatment (Figs. 9 and 10). The clinical stage after four cycles of trastuzumab combined with chemotherapy was cT2N2M0. The patient underwent total gastrectomy, D2 lymphadenectomy and Roux-en-Y anastomosis following the four cycles of the combination therapy. Surgical exploration identified a 7x5 cm tumor in the cardia and fundus of the stomach, with enlarged lymph nodes, and no evident metastatic nodules in the liver, parietal peritoneum, mesenterium or pelvic floor. The macroscopic type of the tumor was classified as Borrmann III (19). The pathological diagnosis was poorly differentiated adenocarcinoma of the stomach. The tumor had invaded the muscular layer. Incisional margins were negative. In addition, cancer cells were identified in the lesser curvature lymph node (2/9), whereas no cancer cells were identified in other lymph nodes (0/10). The pathological TNM stage was ypT2N1M0. The patient received an additional four cycles of XELOX and the trastuzumab regimen at a decreased dose with 100 mg/m² for oxaliplatin and 1,000 mg/m² for Xeloda. After the therapy ceased, the patient received a follow-up every 3 months and remained disease-free at 13 months.

Discussion

Gastric cancer is the fourth most common cancer worldwide in 2008 and the high incidences of gastric cancer are reported in China, Japan and South Korea (20). Gastric cancer is the third most prevalent cause of cancer-associated mortality in males and the second most prevalent in females in China in 2011 (1). Unlike in Japan, screening programs are not performed in China, and the majority of patients with gastric cancer present at initial diagnosis in a more advanced stage (1).

For late stage gastric cancer, surgical resection does not represent the optimal strategy; palliative gastrectomy, chemotherapy, radiotherapy, gastric stent and bypass are the current strategies for these patients (4). The Japanese Gastric Cancer Association guidelines suggest that gastrectomy...
ought to be performed for patients with a single non-curative factor (21). In contrast, the guidelines of three European societies, the European Society for Medical Oncology, the European Society of Surgical Oncology, and the European Society of Radiotherapy and Oncology, suggest that gastrectomy should be performed for patients who respond well to systemic chemotherapy (22). However, the REGATTA trial reported that palliative resection of the primary tumor was not beneficial for patients (23). This conversion treatment may be the optimal choice for patients with late stage gastric cancer; chemotherapy compliance could be improved prior to surgery and certain cytokines may promote tumor growth following surgery (27,28).

In 1997, Nakajima et al first reported conversion surgery for gastric cancer (29). At the same time, they also reported that liver metastasis and peritoneal seeding were difficult to control (29). In addition, Kanda et al revealed that lymph node metastasis and peritoneal dissemination were associated with an improved, and poorer prognosis, respectively (30). To identify patients who may benefit from conversion therapy, Yoshida et al classified late stage gastric cancer into four categories; patients with potentially resectable metastases without peritoneal dissemination represented the optimal candidates for neoadjuvant chemotherapy, while those with marginally resectable metastases without peritoneal dissemination represented the optimal candidates for conversion surgery (31). In a recently reported clinical trial, 40/151 patients with gastric cancer underwent conversion surgery (32). The 5-year overall survival rate of the patients who underwent conversion surgery was 43%, whereas those
who were treated with chemotherapy alone were associated with an overall survival rate of 1%. The patients in the present study presented with lymph node metastasis and responded well to chemotherapy and targeted therapy. Therefore, conversion surgery was performed following four cycles of chemotherapy and targeted therapy.

The ToGA trial confirmed the efficacy and safety of trastuzumab (13). National Comprehensive Cancer Network guidelines suggest that all patients with metastatic disease should be tested for ERBB2 at the time of diagnosis (33). As a first-line treatment, the effectiveness of trastuzumab in palliative therapy has been supported by a previous study (13). Certain case reports have indicated that trastuzumab was successfully applied for conversion surgery in patients with gastric cancer (14,15). Similarly, ERBB2 (3+) was revealed in our patients assessed in the present study upon initial diagnosis of gastric cancer. In the patients evaluated in the present study, targeted therapy was combined with chemotherapy, the patients responded well, and conversion surgeries were performed in the patients. Conversion therapy is a novel therapy concept for which trials are expected.

The present study provided novel insight into conversion therapy for advanced stage gastric cancer. Further study is required to evaluate the efficacy of combining targeted therapy with a chemotherapy regimen in patients with gastric cancer.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Sichuan Provincial Science and Technology Project (grant no. 2014FZ0089).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

SX and XZ wrote the main manuscript. SX and XZ made contribution to conception and design. SX, RX and ZD performed the data collection. XT and JL prepared the figures and made contribution to the pathological data collection.

Ethics approval and consent to participate

Written informed consent was obtained from the patients for the present study and any accompanying images to be published. The Ethics Committee of Sichuan Cancer Hospital (Chengdu, China) approved the present study.

Patient consent for publication

Written informed consent was obtained from the patients for the present study and any accompanying images to be published.

Competing interests

The authors declare that they have no competing interests.

References

1. Chen W, Zheng R, Zeng H, Zhang S and He J: Annual report on status of cancer in China, 2011. Chin J Cancer Res 27: 2-12, 2015.
2. An JY, Ha TK, Noh JH, Sohn T and Kim S: Proposal to subclassify stage IV gastric cancer into IVA, IVB, and IVM. Arch Surg 144: 38-45, 2009.
3. Songun I, Putter H, Kransenberg EM, Sasaki M and van de Velde CJ: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11: 439-449, 2010.
4. Iizushi K and Mori H: Recent strategies for treating stage IV gastric cancer: Roles of palliative gastrectomy, chemotherapy, and radiotherapy. J Gastrointestin Liver Dis 25: 87-94, 2016.
5. Tan P and Yeoh KG: Genetics and molecular pathogenesis of gastric adenocarcinoma. Gastroenterology 149: 1153-1162, 2015.
6. Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG and Salto-Tellez M: A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 63: 839-842, 2010.
7. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Silvo E, et al: Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005.
8. Hechtman JF and Polydorides AD: HER2/neu gene amplification and protein overexpression in gastric and gastro-oesophageal junction adenocarcinoma: A review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 136: 691-697, 2012.
9. Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM and Pui RK: HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: Clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochim Mol Morphol 20: 13-24, 2012.
10. Gómez-Martín C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, Rodríguez-Peralto JL, Hidalgo M and López-Ríos F: HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol 65: 751-757, 2012.
11. Chua TC and Merrett ND: Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-a systematic review. Int J Cancer 130: 2845-2856, 2012.
12. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Taieb LJ, Tang LH, et al: Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: A European and USA International collaborative analysis. Ann Oncol 23: 2656-2662, 2012.
13. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Saeki M, Tomoda T, Yi Y, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for untreated HER2-positive metastatic gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
14. Yamamoto K, Fujiyama T, Tsujinaka T, Hirao M, Nishikawa K, Fukuda Y, Haraguchi N, Miyake M, Asaoka T, Miyamoto A, et al: A case of HER2-positive advanced gastric cancer with extensive lymph node metastasis treated via chemotherapy with a trastuzumab-containing regimen followed by conversion surgery. Gan To Kagaku Ryoho 41: 2296-2298, 2014 (In Japanese).
15. Choda Y, Ninomiya M, Kanazawa T, Sato D, Tokumoto N, Harano M, Matsuoka H, Ojima Y, Idani H, Shiozaki S, et al: Gastric cancer with liver metastasis and peritoneal dissemination treated with conversion surgery to achieve r0 resection after capecitabine, cisplatin, and trastuzumab chemotherapy-a case report. Gan To Kagaku Ryoho 41: 1421-1424, 2014 (In Japanese).
16. Rüschoff J, Hanss M, Bilous M, Hofmann M, Osamura RY, Pennault-Llorca F, van de Vijver M and Viale G: HER2 testing in gastric cancer: A practical approach. Mod Pathol 25: 637-650, 2012.
17. Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC and Lacouture ME: Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 67:1025-1039, 2012.
18. Washington K: 7th edition of the AJCC cancer staging manual: Stomach. Ann Surg Oncol 17: 3077-3079, 2010.

19. Espejo Romero H and Navarrete Siancas J: Classification of gastric cancer in Asia. World J Gastroenterol 20: 4483-4490, 2014.

20. Rahman R, Asombang AW and Ibda JAH: Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines. Oncol Rep 17: 161-167, 2007.

21. Nakajima T, Ota K, Ishihara S, Oyama S, Nishi M, Ohashi Y and Yanagisawa A: Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 4: 203-208, 1997.

22. Kanda T, Yajima K, Kosugi S, Ishikawa T, Akioka Y and Hatakeyama K: Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S1-based chemotherapy: A multi-institute retrospective study. Gastric Cancer 15: 235-244, 2012.

23. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, et al: Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): A phase 3, randomised controlled trial. Lancet Oncol 17: 309-318, 2016.

24. Sougioulitzis S, Syrios J, Xynos ID, Bovaretos N, Kosmas C, Sarantonis J, Dokou A, Tzivras D, Zografos G, Felekouras E, et al: Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: A retrospective analysis. Eur J Surg Oncol 37: 312-318, 2011.

25. Kim KH, Lee KW, Baek SK, Chang HJ, Kim YJ, Park DJ, Kim JH, Kim HH and Lee JS: Survival benefit of gastrectomy ± metastasectomy in patients with metastatic gastric cancer receiving chemotherapy. Gastric Cancer 14: 130-138, 2011.

26. Terashima M: Conversion therapy for gastric cancer: Who can make conversion as successful as Goromaru? Gastric Cancer 19: 685-686, 2016.

27. Wada Y, Yoshida K, Hihara J, Konishi K, Tanabe K, Ukon K, Taomoto J, Suzuki T and Mizuiri H: Sivelestat, a specific neutrophil elastase inhibitor, suppresses the growth of gastric carcinoma cells by preventing the release of transforming growth factor-alpha. Cancer Sci 97: 1037-1043, 2006.